SNCA and Parkinson disease: In more recent years (2021–2025), the research scope expanded to include gender-specific considerations (“male” and “female”), cross-disease insights (“cancer immunotherapy”), and continued deep dives into the role of “alpha-synuclein” in Parkinson’s pathology (Figures 7A, B).